Browsing Tag
GLP-1 therapy
3 posts
Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review
Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next.
Why CVS Caremark’s decision to drop Zepbound could reshape the billion-dollar weight-loss drug war
CVS Caremark faces a lawsuit after dropping Eli Lilly’s Zepbound from coverage. Explore patient, investor, and payer implications in the GLP-1 market battle.
Neodyne Biosciences and Gan & Lee Pharmaceuticals reveal major clinical advances in diabetes care at ADA 2025
Neodyne Biosciences and Gan & Lee Pharmaceuticals presented major ADA 2025 clinical results showing new treatment paths for lipohypertrophy and type 2 diabetes.